Ind-Swift Laboratories Ltd. (INDSWFTLAB): Ind-Swift Laboratories Share Price Rises 12.95% as Small Cap Stock Clears Threshold

Ind-Swift Laboratories climbed to Rs 267.8, up 12.95% today, taking its market capitalisation to Rs 1,986.64 crore and placing the stock among notable small-cap gainers.

Ind-Swift Laboratories Share Price jumped to Rs 267.8 on 11 August 2026, up Rs 30.7 or 12.95% from the previous close of Rs 237.1, lifting the company’s market capitalisation to Rs 1,986.64 crore.

For readers tracking Ind-Swift Laboratories Share Price Today, the stock opened at Rs 248.05, touched a day high of Rs 270 and did not slip below its opening level, with the day low also at Rs 248.05. That intraday pattern points to strong early buying support rather than a brief spike that faded quickly. Total traded volume reached 5,56,516 shares across exchanges, including 25,993 shares on BSE and 5,30,523 shares on NSE, while reported turnover stood at Rs 0.7 crore on the exchange flagged in the event data.

What is important for investors is that the supplied data confirms the price event but does not establish a company-specific catalyst. That means the focus shifts to what the numbers do show: strong price action, a small-cap pharma counter in the Healthcare sector, a P/E ratio of 48.45, a P/B ratio of 1.41, ROE of -0.78 and ROCE of 8.31. In this Univest analysis, those figures help explain why the stock is trending in Share Market Today and what market participants may want to monitor next.

Ind-Swift Laboratories Ltd. (INDSWFTLAB) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 267.8
Previous Close	Rs 237.1
Today's Change	+Rs 30.7 (+12.95%)
Day Open	Rs 248.05
Day High	Rs 270
Day Low	Rs 248.05
Current Volume (BSE)	25,993
BSE Traded Volume	25,993
NSE Traded Volume	5,30,523
Combined NSE + BSE Volume	5,56,516
Turnover	Rs 0.7 crore
Market Capitalisation	Rs 1,986.64 crore
Market Cap Category	Small Cap

Ind-Swift Laboratories Ltd. (INDSWFTLAB) traded at Rs 267.8. versus the previous close of Rs 237.1, a rise of 12.95%. The stock opened at Rs 248.05, reached Rs 270, touched Rs 248.05. Reported volume was 25,993.

Ind-Swift Laboratories Ltd. (INDSWFTLAB) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 1,986.64 crore
P/E Ratio	48.45x
P/B Ratio	1.41x
ROE	-0.78%
ROCE	8.31%
EPS	Rs 4.89
Dividend Yield	0%

Ind-Swift Laboratories Ltd. was valued at a P/E ratio of 48.45x, a P/B ratio of 1.41x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of -0.78% and ROCE of 8.31%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Per-share and shareholder-return metrics included EPS of Rs 4.89, dividend yield of 0%. Dividend yield is a current or historical ratio and does not guarantee future distributions.

Ind-Swift Laboratories Share Price is now drawing closer scrutiny because the market move is large enough to push investors beyond headline price action and into financial analysis. At a market capitalisation of Rs 1,986.64 crore, the company sits firmly in the small-cap bracket, which is relevant for risk, liquidity and re-rating discussions but does not itself say whether the stock is cheap or expensive. That requires looking at the supplied valuation and profitability numbers together.

The stock is trading at a P/E ratio of 48.45 and a P/B ratio of 1.41. On earnings valuation alone, that P/E suggests the market is placing a multiple on current profitability that is above several listed peers and above the industry median discussed later, though still below the industry average because the benchmark range is extremely wide. The P/B ratio of 1.41 is more restrained and sits below the industry median of 1.8, which shows that book-value valuation is not as stretched as the earnings multiple might imply.

Profitability metrics present a mixed picture. ROE stands at -0.78, which indicates negative return on shareholder equity on the supplied basis, while ROCE is 8.31, showing the company is generating a positive but moderate return on capital employed. That contrast is important in any Ind-Swift Laboratories Fundamental Analysis because it suggests that balance-sheet and earnings quality should be read carefully rather than reduced to one ratio.

EPS is Rs 4.89, which means the current share price is being valued at 48.45 times the earnings attributable to each share. Dividend yield is 0, so the present valuation case in the supplied data is not supported by an ongoing cash yield. Instead, market attention appears concentrated on price movement and relative positioning within the pharmaceuticals space.

For investors reading Ind-Swift Laboratories Stock News, the combination is neither uniformly strong nor uniformly weak. The company has a modest P/B ratio, a high P/E relative to the industry median, negative ROE and positive ROCE. In Univest’s view, that mix provides context for today’s interest but also argues for examining how the company stands against its Healthcare and Pharmaceuticals & Drugs benchmarks.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	48.45x
Benchmark Median P/E	25.7x
Benchmark Average P/E	69.27x
Benchmark P/E Range	3.08x to 3,396.3x
Company P/B Ratio	1.41x
Benchmark Median P/B	1.8x
Company ROE	-0.78%
Benchmark Median ROE	10.59%
Company ROCE	8.31%
Benchmark Median ROCE	12.98%
Company Market Capitalisation	Rs 1,986.64 crore
Benchmark Median Market Cap	Rs 146.99 crore

Ind-Swift Laboratories Ltd. (INDSWFTLAB) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Ind-Swift Laboratories Ltd. (INDSWFTLAB) has a P/E ratio of 48.45x, which is above the benchmark median of 25.7x, a difference of +88.52%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Ind-Swift Laboratories Ltd. (INDSWFTLAB) has a ROE of -0.78%, which is below the benchmark median of 10.59%, a difference of -107.37%. Ind-Swift Laboratories Ltd. (INDSWFTLAB) has a ROCE of 8.31%, which is below the benchmark median of 12.98%, a difference of -35.98%.

Track today's top gainers through the Univest top gainers screener. The peer table below provides the company-level comparison.

Ind-Swift Laboratories operates in Healthcare under the Pharmaceuticals & Drugs industry, and the benchmark data offers useful context because it covers 137 companies in the same industry. That scope matters: today’s price rise happened in a broad listed universe where valuation and profitability ranges are wide, so the stock’s numbers need to be read relative to that backdrop rather than in isolation.

The company’s P/E ratio is 48.45. Within the same-industry benchmark, the median P/E is 25.7, the average is 69.27, the minimum is 3.08 and the maximum is 3,396.3 across 104 companies with available P/E data. That places Ind-Swift Laboratories above the industry median but below the average, which implies the stock is not among the cheapest on earnings, yet it is also far from the most expensive when set against the full sector range. For P/B, the company stands at 1.41 versus an industry median of 1.8 and average of 2.49 across 136 companies, suggesting a lower-than-median book-value multiple.

Profitability tells a more challenging story. Company ROE is -0.78, below the industry median of 10.59 and the average of 8.24. ROCE is 8.31, also below the industry median of 12.98 and average of 15.72. In simple terms, the stock’s valuation on book value appears less demanding than the benchmark, but its return ratios are also weaker than typical same-industry readings.

Market capitalisation adds another perspective. Ind-Swift Laboratories has a market cap of Rs 1,986.64 crore, compared with an industry median of Rs 146.99 crore and an average of Rs 500.01 crore. That means the company is materially larger than the typical firm in this industry sample, though still below the maximum benchmark company market cap of Rs 3,032.97 crore. In Univest coverage, this combination makes the stock notable: a relatively larger listed pharma name in its peer set, with middling-to-weak return ratios but a lower P/B than the benchmark median.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Dishman Carbogen Amcis Ltd.	DCAL	3,032.97	0	0.76	-2.89	-0.26
Hikal Ltd.	HIKAL	2,799.54	0	2.32	15.22	16.15
Kwality Pharmaceuticals Ltd.	KPL	2,707.2	40.09	9.77	28.21	26.35
Beta Drugs Ltd.	BETA	2,631.45	66.92	10.59	18.65	22.17
Panacea Biotec Ltd.	PANACEABIO	2,531.49	0	8.67	0	5.36

Ind-Swift Laboratories Ltd. (INDSWFTLAB) has a P/E ratio of 48.45x compared with the displayed peer median of 0x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of -0.78% compares with a peer median of 15.22% across the companies shown in the table. ROCE stood at 8.31% versus the displayed peer median of 16.15%, providing a capital-efficiency comparison. Ind-Swift Laboratories Ltd. (INDSWFTLAB) has a market capitalisation of Rs 1,986.64 crore. Among the 5 peers shown, 5 have a larger market capitalisation.

Ind-Swift Laboratories Share Price is gaining attention partly because its market cap of Rs 1,986.64 crore places it close to a cluster of listed pharmaceutical peers. Against Hikal Ltd., which has a market cap of Rs 2,799.54 crore, Ind-Swift is smaller and also trails meaningfully on profitability, as Hikal reports ROE of 15.22 and ROCE of 16.15 compared with Ind-Swift’s ROE of -0.78 and ROCE of 8.31. Hikal’s P/B of 2.32 is above Ind-Swift’s 1.41, showing the market assigns a richer book-value multiple to the stronger-return business.

Versus Kwality Pharmaceuticals Ltd., the comparison is even sharper on return ratios. Kwality has a P/E of 40.09, lower than Ind-Swift’s 48.45, while posting ROE of 28.21 and ROCE of 26.35. That means Ind-Swift currently trades at a higher earnings multiple despite weaker reported profitability. Beta Drugs Ltd. trades at a higher P/E of 66.92, but it also shows stronger ROE of 18.65 and ROCE of 22.17, again highlighting the gap between valuation and returns.

NGL Fine-Chem Ltd. is another relevant marker. Its P/E stands at 44.48, slightly below Ind-Swift, while ROE of 27.9 and ROCE of 33.91 are substantially higher. By contrast, Venus Remedies Ltd. has a lower P/E of 17.49 and ROCE of 7.89, which is close to Ind-Swift’s 8.31, though Venus still shows positive ROE of 9.85 against Ind-Swift’s negative reading.

Dishman Carbogen Amcis Ltd. has a larger market cap of Rs 3,032.97 crore and weaker ROE of -2.89 with ROCE of -0.26. Panacea Biotec Ltd. has ROE of 0 and ROCE of 5.36, both modest. On balance, Ind-Swift sits in the middle of this peer pack on scale, but its profitability metrics are weaker than several directly comparable pharmaceutical names while its P/E remains elevated relative to some of them. That is an important point for any Ind-Swift Laboratories Stock Analysis.

Why Investors Are Watching Ind-Swift Laboratories

Today’s move has put the stock on the radar because the gain was large enough to qualify under the Small Cap price-rise framework, and the intraday structure showed sustained strength rather than a fleeting jump. For investors following Stocks Rising Today and Market Movers, the interest is not only about the 12.95% move but also about how that move interacts with valuation, profitability and sector positioning.

• Verified price action: the stock rose from Rs 237.1 to Rs 267.8, after opening at Rs 248.05 and touching Rs 270.
• Exchange participation: total volume reached 5,56,516 shares, with 5,30,523 shares on NSE and 25,993 on BSE.
• Category relevance:<
• Valuation context: P/E is 48.45 and P/B is 1.41, creating a mixed valuation picture.
• Profitability context: ROE is -0.78 while ROCE is 8.31, both below key industry benchmark levels.
• Sector position: the stock operates in Healthcare, specifically Pharmaceuticals & Drugs, where benchmark valuation and return ranges are wide.

What investors may monitor next is whether the stock continues to hold a large part of today’s gains, how its valuation is discussed relative to stronger-return peers, and whether future company updates change the balance between market interest and underlying profitability. Univest readers often focus on that intersection because a top gainer tag alone rarely tells the full story.

About Ind-Swift Laboratories

Ind-Swift Laboratories Ltd. is part of the Healthcare sector and operates within the Pharmaceuticals & Drugs industry. That places the company in one of the most actively tracked spaces in the Indian Stock Market, where investors often compare businesses through earnings multiples, return ratios and scale within a broad listed universe.

Based on the verified company classification supplied for this article, Ind-Swift Laboratories should be read primarily as a pharmaceutical business rather than through unrelated sector themes. In practical market terms, that means its Share Price, stock performance and market perception are usually assessed against other drug and healthcare counters, not against industrial, banking or consumer names. Its present market capitalisation of Rs 1,986.64 crore also makes it larger than the median company in the same-industry benchmark, which can increase visibility when it appears in Top Gainers Today screens.

Because the supplied data set is focused on price action, valuation, peer comparison and benchmark context, the clearest current company profile is this: Ind-Swift Laboratories is a listed pharma stock operating in an industry where investor attention often turns quickly toward P/E, P/B, ROE, ROCE and relative market cap. Today’s move therefore matters not just as a one-session rise, but as an event that brings the company back into active comparison with listed pharmaceutical peers across NSE and BSE.

Track Ind-Swift Laboratories Share Price on Univest

Use Ind-Swift Laboratories Ltd. (INDSWFTLAB) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top gainers lists and related market analysis.

Investors who want to follow Ind-Swift Laboratories Share Price more closely can track the stock on Univest for live price updates, market-cap changes and broader stock analysis. Univest also helps users monitor valuation ratios such as P/E and P/B, profitability indicators including ROE and ROCE, 52-week levels, exchange-wise activity and other market insights that add context beyond one day’s move.

For readers searching Ind-Swift Laboratories Share Price Today, Ind-Swift Laboratories Stock News or Ind-Swift Laboratories Share Price Update, using a structured platform matters because it keeps price action, fundamentals and sector context in one place. That is especially useful after a sharp move like today’s, when market attention can shift quickly from headline momentum to deeper comparison across peer stocks.

Frequently Asked Questions

Why is Ind-Swift Laboratories Share Price rising today?

Ans. Ind-Swift Laboratories Share Price rose because the stock gained 12.95% in the session, moving from Rs 237.1 to Rs 267.8. The supplied data confirms the price event and shows strong intraday holding, but it does not establish a company-specific catalyst.

What is Ind-Swift Laboratories Share Price Today?

Ans. Ind-Swift Laboratories Share Price Today is Rs 267.8. That is Rs 30.7 above the previous close of Rs 237.1, translating into a 12.95% gain, with the session range so far running from Rs 248.05 to Rs 270.

How much volume was traded in Ind-Swift Laboratories today?

Ans. Total traded volume in Ind-Swift Laboratories stood at 5,56,516 shares. Of this, 5,30,523 shares were traded on NSE and 25,993 shares on BSE, showing that most of the day’s activity was concentrated on the NSE platform.

Did Ind-Swift Laboratories clear the qualifying bar for its market-cap category?

Ans. Yes. Ind-Swift Laboratories is classified in the Small Cap category, and the supplied event data confirms that today’s 12.

What does today’s intraday price action show for Ind-Swift Laboratories?

Ans. The stock opened at Rs 248.05, touched a high of Rs 270 and recorded a low of Rs 248.05. That means the price never fell below the opening level in the supplied session data, reflecting sustained buying interest.

What are the key valuation ratios for Ind-Swift Laboratories?

Ans. Ind-Swift Laboratories is trading at a P/E ratio of 48.45 and a P/B ratio of 1.41. Those figures place its earnings multiple above the industry median P/E of 25.7, while its P/B sits below the industry median of 1.8.

How profitable is Ind-Swift Laboratories based on the supplied data?

Ans. The supplied profitability metrics are mixed. ROE stands at -0.78, indicating a negative return on equity, while ROCE is 8.31, showing a positive return on capital employed, though both are below corresponding industry median benchmark readings.

What are the EPS and dividend yield of Ind-Swift Laboratories?

Ans. Ind-Swift Laboratories reports EPS of Rs 4.89 and a dividend yield of 0. EPS shows the earnings attributable to each share, while the zero dividend yield indicates there is no current historical payout yield reflected in the supplied data.

How does Ind-Swift Laboratories compare with pharma peers?

Ans. Ind-Swift Laboratories has a market cap of Rs 1,986.64 crore, lower than peers such as Hikal and Kwality Pharmaceuticals. Its ROE of -0.78 and ROCE of 8.31 are weaker than several peers, while its P/E of 48.45 remains elevated.

What sector does Ind-Swift Laboratories belong to?

Ans. Ind-Swift Laboratories belongs to the Healthcare sector and operates in the Pharmaceuticals & Drugs industry. The same-industry benchmark used here covers 137 companies, providing context for its valuation, profitability and market-cap positioning.